STOCK TITAN

Volitionrx - VNRX STOCK NEWS

Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.

VolitionRx Limited (VNRX) is pioneering epigenetic diagnostics through its nucleosomics platform, developing non-invasive blood tests for early cancer detection and NETosis-related conditions. This resource provides investors and healthcare professionals with comprehensive access to verified company developments and clinical milestones.

Our curated news collection delivers timely updates on regulatory progress, partnership announcements, and research breakthroughs. Users will find essential information spanning clinical trial results, licensing agreements, veterinary diagnostic expansions, and financial performance reports.

The page features critical updates including technology validations, international market entries, and peer-reviewed study publications. All content is rigorously verified to ensure accuracy and relevance for strategic decision-making.

Bookmark this page for structured access to VolitionRx's evolving diagnostic solutions across human and animal health sectors. Check regularly for authoritative reporting on innovations transforming routine disease detection through advanced epigenetic analysis.

Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) announced the publication of a significant paper in Scientific Reports about its Nu.Q® Capture technology. This paper details a novel method for detecting histone modifications in cancer patients' blood, potentially leading to new biomarkers for colorectal cancer. CEO Cameron Reynolds highlighted the publication as a crucial advancement in liquid biopsy diagnostics. The study revealed that Nu.Q® Capture allows precise analysis of nucleosomes with minimal plasma, underscoring its potential in biomarker discovery and cancer diagnosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.51%
Tags
none
-
Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) announced the appointment of Dr. Tom Butera DVM as CEO of Volition Veterinary Diagnostics Development LLC, effective May 1, 2021. Dr. Butera, who brings extensive experience in veterinary healthcare, aims to position the Nu.Q® Vet Cancer Screening Wellness Test as a leading diagnostic tool for veterinarians. Following his beta launch in Texas, he plans international expansions in Asia and Europe, establishing a robust sales and distribution model. Dr. Gaetan Michel remains COO, ensuring continuity during this transition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.2%
Tags
management
-
Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) announced the appointment of Kim Nguyen and Richard Brudnick to its Board of Directors, effective March 25, 2021. Nguyen will chair the Compensation Committee while Brudnick will serve on the Audit and Compensation Committees. The company aims to transition to the commercialization phase of its Nu.Q® technology for cancer diagnostics. Nguyen brings HR expertise from Google APAC, and Brudnick has extensive experience in business development within the pharmaceutical sector. This strategic addition is expected to enhance Volition's operational management as it approaches product launches.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.2%
Tags
management
Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) announced a significant advancement with the launch of its first product, the Nu.Q® Vet Cancer Screening Test, generating initial sales revenue. The company engaged Diagnostic Oncology CRO LLC for a pivotal U.S. regulatory trial for Non-Hodgkin's Lymphoma, expanding its research into NETosis related to COVID-19 and sepsis. Volition's cash position strengthened to approximately $40 million after a public offering, while it enhanced its intellectual property portfolio with 64 patents. The company is poised for growth in 2021 with beta launches planned in Asia and Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.24%
Tags
-
Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) announces promising data on its Nu.Q® assay presented at the International Society for Apheresis meeting. The study conducted with Santersus AG shows that the Nu.Q® assay effectively monitors the removal of Neutrophil Extracellular Traps (NETs) in a pig model of sepsis. Results indicate that this innovative treatment can remove up to 99% of circulating NETs, potentially offering new avenues for treating various diseases, including sepsis, COVID-19, and cancer. Further studies are underway for human trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.03%
Tags
none
-
Rhea-AI Summary

VolitionRx Limited (VNRX) will host a conference call on March 23, 2021 at 8:00 a.m. ET to discuss its financial and operational results for the full fiscal year 2020. The call will be led by CEO Cameron Reynolds and CFO Terig Hughes, among others, providing updates on clinical trials, key events from 2020, and future milestones. Investors can access the call via a live audio webcast or through dial-in options. A replay will be available until April 6, 2021. VolitionRx focuses on developing blood tests for cancer diagnosis, leveraging its Nucleosomics technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.67%
Tags
Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) announces presentations at six virtual conferences in March 2021.

CEO Cameron Reynolds and Executive VP Scott Powell will discuss the company's business, clinical, regulatory, and operational milestones. Key events include:

  • H.C. Wainwright Global Life Sciences Conference on March 9.
  • Maxim 2021 Emerging Growth Conference from March 17-19.
  • Life Sciences Investor Forum on March 25.

Volition focuses on diagnostic tests for cancers using Nucleosomics™ technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
conferences
-
Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) announced the closing of its underwritten public offering of 3,809,524 shares, raising approximately $20 million before expenses. All shares were sold by Volition, and the underwriter has an option to purchase an additional 571,428 shares. The funds will be used for general corporate purposes, including product development and potential acquisitions. The offering was conducted under a previously filed shelf registration statement with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
-
Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) announced a public offering of 3,809,524 shares of common stock, priced to generate approximately $20 million in gross proceeds. The offering is expected to close on February 12, 2021, pending customary conditions. Cantor Fitzgerald & Co. is managing the offering, which includes an option for the underwriter to purchase an additional 571,428 shares. Net proceeds will fund general corporate purposes, including product development and potential acquisitions. The last reported share price was $6.27.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.91%
Tags
Rhea-AI Summary

VolitionRx Limited (NYSE AMERICAN: VNRX) has announced an underwritten public offering of its common stock, with all shares to be sold by the company. The offering is subject to customary closing conditions and includes a 30-day option for the underwriter to purchase an additional 15% of shares. The offering is conducted under an effective shelf registration statement filed with the SEC. This is part of Volition's strategy to fund its diagnostic products based on the Nucleosomics™ platform, aimed at early disease detection and diagnosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.91%
Tags
Volitionrx

NYSE:VNRX

VNRX Rankings

VNRX Stock Data

48.18M
73.27M
23.38%
20.36%
0.61%
Medical Devices
In Vitro & in Vivo Diagnostic Substances
Link
United States
HENDERSON